Aperio Group LLC Boosts Holdings in Zoetis (ZTS)
Aperio Group LLC raised its position in Zoetis (NYSE:ZTS) by 5.9% during the 1st quarter, Holdings Channel reports. The firm owned 265,938 shares of the company’s stock after acquiring an additional 14,750 shares during the quarter. Aperio Group LLC’s holdings in Zoetis were worth $22,208,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Zoetis in the fourth quarter valued at $108,000. Mckinley Capital Management LLC Delaware acquired a new stake in Zoetis in the first quarter valued at $134,000. We Are One Seven LLC acquired a new stake in Zoetis in the fourth quarter valued at $120,000. Premia Global Advisors LLC acquired a new stake in Zoetis in the fourth quarter valued at $122,000. Finally, Icon Wealth Partners LLC acquired a new stake in Zoetis in the fourth quarter valued at $127,000. 92.59% of the stock is currently owned by institutional investors.
ZTS opened at $82.85 on Thursday. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. The firm has a market cap of $40.67 billion, a P/E ratio of 34.52, a P/E/G ratio of 1.86 and a beta of 0.97. Zoetis has a 52 week low of $82.05 and a 52 week high of $83.07.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, July 20th will be paid a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, July 19th. Zoetis’s payout ratio is 20.83%.
In other Zoetis news, insider Heidi C. Chen sold 37,453 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kristin C. Peck sold 4,877 shares of the firm’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total value of $407,034.42. Following the completion of the sale, the insider now directly owns 42,652 shares in the company, valued at $3,559,735.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,829 shares of company stock worth $9,626,877. 0.35% of the stock is owned by corporate insiders.
Several research firms have weighed in on ZTS. BMO Capital Markets reissued a “hold” rating and issued a $80.00 target price on shares of Zoetis in a report on Wednesday. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the company a “buy” rating in a report on Wednesday. Craig Hallum reissued a “buy” rating and issued a $94.00 target price (up previously from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. Piper Jaffray reissued a “buy” rating and issued a $86.00 target price on shares of Zoetis in a report on Thursday, January 18th. Finally, ValuEngine raised Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $82.67.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.